Beta Bionics (BBNX) Net Equity Issued and Repurchased (2025)

Beta Bionics (BBNX) posted Net Equity Issued and Repurchased of -$904000.0 for Q4 2025, down 100.46% sequentially from $195.4 million in Q1 2025.

Beta Bionics (BBNX) Net Equity Issued and Repurchased (2025) Analysis & Trends

Beta Bionics has reported Net Equity Issued and Repurchased for 1 years, with the latest figure at -$904000.0 in Q4 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$904000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $194.5 million (changed N/A YoY) and the FY2025 annual result came in at $194.5 million, up 226.06% from the prior year.
Net Equity Issued and Repurchased retreated to -$904000.0 in Q4 2025 per BBNX's latest filing, from $195.4 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $195.4 million in Q1 2025 and troughed at -$904000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn	-
2	Stryker	128.79 Bn	125.32 Bn	4.50 Bn	-
3	Medtronic	119.30 Bn	110.08 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	73.50 Bn	72.96 Bn	3.85 Bn	-
5	Edwards Lifesciences	52.11 Bn	47.86 Bn	1.35 Bn	-
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn	-
7	GE HealthCare Technologies	34.05 Bn	31.94 Bn	2.18 Bn	-
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn	-
9	Steris	23.15 Bn	22.67 Bn	684.20 Mn	-
10	Beta Bionics	845.25 Mn	664.76 Mn	18.90 Mn	-

Download Data